Astria advances innovative therapies for hereditary angioedema and atopic dermatitis. Strong cash position supports pivotal ...

Amgen has made a play in a hot area of immunology R&D, paying $400 million upfront to claim rights to an OX40-targeting drug from Kyowa Kirin that is ready for phase 3 testing for atopic ...

The partnership dates back to 2015, when Incyte paid $60 million upfront for access to four checkpoint programs, including ...

Sanofi has announced encouraging findings from the second part of a study with the OX40 antibody amlitelimab, which showed sustained improvement in treating moderate to severe atopic dermatitis ...

The firm's decision follows Astria's announcement of the initiation of a Phase 1a study for STAR-0310, a monoclonal antibody and OX40 antagonist, aimed at treating atopic dermatitis and ...

Agenus (AGEN) entered into a License, Development, and Commercialization Agreement with Incyte (INCY), under which Incyte ...

For these reasons, molecules targeting direct activation of immune cells, including antibodies to receptors such as OX40, CD40 and others on immune cells with a stimulatory mechanism of action ...